NEFL and amyotrophic lateral sclerosis: The strength of our study lies in the comprehensive approach to examine the association of a diverse array of clinical chemistry biomarkers, both individually and jointly, with survival outcomes in different time windows after ALS diagnosis, as well as with functional decline and NfL measured in CSF.